News

Imprime PGG is an immunomodulatory drug, used as a treatment for cancer. The open label multicentre randomised trial involving 90 patients assessed the safety and efficacy of Imprime

The formulation is used to treat diseases associated with inappropriate insulin levels. Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of

Both the companies combined UHN’s human pluripotent stem cell biology expertise with VistaGen’s Human Clinical Trials in a Test TubeTM stem cell technology platform. The platform is believed

Vyndaqel is a transthyretin stabilizer which prevents the formation of misfolded proteins and the subsequent amyloid deposits that lead to neurodegeneration and decline of neurologic function. A pivotal

The deal covers Mobile Intelligence Key Account Management (KAM), Key Opinion Leader (KOL) and Configuration and Administration Tools. It also includes OneKey, the healthcare professional database; help desk

The software is believed to aid in pharmaceutical actions, generate efficiencies in stock management and dispensing processes, provide the required information to implement performance and risk management. In

Imipenem-cilastatin, a generic version of Merck’s Primaxin is a carbapenem that belongs to the beta-lactam class of antibiotics. The medication will be made available in 250 mg and

The company will produce ADI-PEG 20 products and targets an annual production value of around $2bn, news.cens.com reported. Polaris developed ADI-PEG 20 drug for the treatment of cancers.

Martino served at a cancer therapeutics company – Sonus Pharmaceuticals as president and CEO from 1999 to 2008 where he developed company’s lead cancer therapeutic through a pivotal